Saltar al contenido
  • Home
  • About Us
  • Services
  • Courses
  • News and Events
  • Contact Us
Menú
  • Home
  • About Us
  • Services
  • Courses
  • News and Events
  • Contact Us
Buscar
Cerrar este cuadro de búsqueda.

rare genetic disorder

  1. Inicio>
  2. News and Events>
  3. rare genetic disorder
Lee más sobre el artículo EMA recommends authorisation of first therapy to treat rare genetic disorder

EMA recommends authorisation of first therapy to treat rare genetic disorder

EMA has recommended granting a marketing authorisation in the European Union for Upstaza (eladocagene exuparvovec). This is a gene therapy for the treatment of adult and paediatric patients with severe…

Continuar leyendoEMA recommends authorisation of first therapy to treat rare genetic disorder

Recent Posts

  • FDA Approves First Treatment for Rare Inherited Blood Disorder
  • FDA Guidance for Industry. Human Gene Therapy for Rare Disease
  • New FDA Pilot to Accelerate the Development of Rare Disease Therapies
  • FDA announces next Cellular, Tissue and Gene Therapies Advisory Committee
  • FDA’s Guideline on Human Gene Therapy for Retinal Disorders

Recent Comments

  1. EMA's 2022 Annual Report published - Reviopharma en EMA’s 2022 Highlights on Human Medicines and Advanced Therapies

Revio is a Regulatory Affairs Consultancy – Created to support biopharmaceutical companies and public institutions, working with Advanced Therapy Medicinal Products (ATMPs)

Facebook-f Twitter Pinterest Linkedin

About

Home

About Us

Services

News & Events

Contact Us

Contact

TELEPHONES

+34 656 659 636

EMAIL

regaffairs@reviopharma.com

Legal

Cookies Policy

Data Protection

Legal Notice

Privacy policy

Social Networks

Copyright © 2023 – All Right Reserved – Powered by: Headteam.marketing

×
×

Carrito